Document is current

Article History

Received: 27 January 2026

Accepted: 24 February 2026

First Online: 3 March 2026

Declarations

:

: The studies involving human participants were reviewed and approved by Comité de protection des personnes and registered on clinical trial with number: ClinicalTrials.gov ID NCT02669810 and EudraCT 2014-001476-63. Details of the EXCELLENT Study as follows: - ClinicalTrials.gov Identifier : NCT02669810. - First Submitted : 2016-01-25. - First Submitted That Met QC Criteria : 2016-01-27. - First Posted (Estimated) : 2016-02-01. - Study Start Date (Actual) : 2015-09-25. - Primary Completion Date (Actual) : 2024-03-15. - Study Completion Date (Actual) : 2024-03-15.

: All patients provided written informed consent for the use and publication of data derived from this study.

: All patients provided written informed consent to participate in this study, in accordance with Ethical Permit and registration on ClinicalTrials.gov ID NCT02669810 and EudraCT 2014-001476-63.

: Authors declare that the submitted work is original and has not been published before and that the work is not under consideration for publication elsewhere. Jerome Roncalli: Conceptualization of the study, principal investigator at Toulouse site, oversight of clinical methodology, patient recruitment, and critical revisions of the manuscript. François Roubille: Clinical investigation lead at Montpellier site, patient recruitment, data interpretation, and critical manuscript revision. Philippe Henon: Co-founder of CellProthera, responsible for design and manufacturing of ProtheraCytes®, contributed to trial design and translational insights. Gilles Montalescot: Clinical investigation lead at Montpellier site, patient recruitment, data interpretation, and critical manuscript revision. Deepak L. Bhatt. Clinical investigation lead at Montpellier site, patient recruitment, data interpretation, and critical manuscript revision. Guillaume Trebuchet: Coordinated trial logistics, data management, and contributed to manuscript revisions from, contributed to the biological and technical aspects of the manuscript. Matthieu de Kalbermatten: Supported trial logistics, data management, and contributed to manuscript revisions from CellProthera side. Ibon Garitaonandia: Provided scientific oversight on cell therapy protocol, participated in data interpretation and manuscript review. David M. Smadja: Wrote the manuscript and coordinated the project.